Figure 5

Therapeutic targets in the aggressiveness gene list. (a) The TNBC cell lines, MDA-MB-231, SUM159PT and Hs578T were treated with control siRNA (Scrambled, Sc CTRL) or siRNA targeting the specified genes, and the survival of these cells was compared on day 6. Data show the average from the three cell lines where each cell line was treated in triplicate. *P<0.05 and ***P<0.001 from one-way ANOVA analysis performed using GraphPad Prism. Data for individual cell lines are shown in Supplementary Table 2. (b) A panel of breast cancer cell lines was used to prepare lysates for immunoblotting of TTK. Tubulin was used as the loading control. (c) Dose response curves for the treatment of breast cancer cell lines in the absence or presence of escalating doses of the TTK inhibitor (TTKi) AZ3146. The survival of cells was measured using the CellTitre MTS/MTA assay carried out 6 days after treatment. Percentage survival (n=3 per dose) was calculated as the percentage of the signal from treated cells to that from control cells. (d) The concentration of TTK required to affect the survival of 50% of the cells (IC50) was measured by GraphPad Prism from the dose response curves in C for each cell line.